Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation

[1]  B. Bodaghi,et al.  Primary CNS lymphoma , 2015, Current opinion in ophthalmology.

[2]  N. Brousse,et al.  Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma , 2013, Leukemia & lymphoma.

[3]  J. Finke,et al.  Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Thiel,et al.  Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Straube,et al.  Rituximab significantly improves complete response rate in patients with primary CNS lymphoma , 2012, Journal of Neuro-Oncology.

[6]  P. Duggan,et al.  Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience , 2012, Leukemia & lymphoma.

[7]  M. Weller,et al.  Pathogenesis and management of primary CNS lymphoma , 2012, Expert review of anticancer therapy.

[8]  A. Huitema,et al.  Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma , 2012, Leukemia & lymphoma.

[9]  J. Gribben,et al.  Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention‐to‐treat analysis , 2012, British journal of haematology.

[10]  G. Nikkhah,et al.  Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  K. Hoang-Xuan,et al.  Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? , 2011, Journal of Neuro-Oncology.

[12]  E. Thiel,et al.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.

[13]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Chamberlain,et al.  High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. , 2010, Neuro-oncology.

[15]  R. Fimmers,et al.  Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study , 2009, Journal of Neuro-Oncology.

[16]  E. Thiel,et al.  Primary central nervous system lymphoma , 2008, Cancer.

[17]  D. Correa,et al.  Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Deangelis,et al.  Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Bay,et al.  High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group , 2006, Bone Marrow Transplantation.

[20]  J. Armitage,et al.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Thiel,et al.  Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma , 2005, British journal of haematology.

[22]  R. Fimmers,et al.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Deangelis,et al.  Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma? , 2002, Journal of Neuro-Oncology.

[24]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[25]  L. Deangelis,et al.  Leptomeningeal tumor in primarchy central nervous system lymphoma: Recognition, significance, and implications , 1995, Annals of neurology.

[26]  D. Correa,et al.  Cognitive functions in primary CNS lymphoma after single or combined modality regimens. , 2012, Neuro-oncology.